12:00 AM
Apr 15, 2013
 |  BioCentury  |  Emerging Company Profile

Abcodia: Banking on biomarkers

Abcodia looking for predictive serum biomarkers for early detection of cancer

Abcodia Ltd. is using blood samples that have been taken annually by the U.K. Collaborative Trial for Ovarian Cancer Screening to identify serum biomarkers that can detect breast, lung, pancreatic and colorectal tumors at least one year before symptomatic presentation.

Cancer biomarkers identified through comparisons of samples from diagnosed cancer patients and matched healthy controls may not be useful for widespread screening as they rely on threshold levels that may miss cancer in individuals with biomarkers that are rising but low, or falsely diagnose a healthy subject with naturally high levels.

"We're still very reliant on symptomatic presentation of cancer, which in many cases leads to a late diagnosis," said CEO Julie Barnes. She estimated that current biomarkers for cancer have a sensitivity of about 70% and still produce many false positives.

Ideally biomarkers would be identified by comparing samples from prediagnosed cancer patients and matched healthy controls over time; however, regular samples taken years before diagnosis - or...

Read the full 779 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >